Shopping Cart
- Remove All
- Your shopping cart is currently empty
Casein Kinase inhibitor A51 is an orally active casein kinase 1α (CK1α) inhibitor with anticancer activity that induces apoptosis in leukemia cells, and may be used in the study of neck cancers, acute myeloid leukemia, breast and prostate cancers.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
2 mg | $399 | In Stock |
Description | Casein Kinase inhibitor A51 is an orally active casein kinase 1α (CK1α) inhibitor with anticancer activity that induces apoptosis in leukemia cells, and may be used in the study of neck cancers, acute myeloid leukemia, breast and prostate cancers. |
Targets&IC50 | CDK7:1.3 nM (Kd), CDK9:4 nM (Kd) |
In vitro | VEGFR2-IN-1 ( 0.1,1,10,100μM ; 48 h ) were effective selective inhibitors of Mcf-7, Mda-Mb-231 and Mcf-10A : MCF-7 ( IC50 = 1.18 μM ), MDA-MB-231 ( IC50 = 10.49 μM ), MCF-10A ( IC50 = 24.76 μM )[1]. |
In vivo | In Male Swiss albino mice, 21-28 g ( Xenograft model ),VEGFR2-IN-1 ( 4.2 mg/kg; i.p.; once a days ; 7 days ) Showed anticancer activity by having a tumor inhibition ratio of 54.2 % [1]. |
Molecular Weight | 360.88 |
Formula | C18H25ClN6 |
Cas No. | 2079068-74-7 |
Smiles | Cn1ncc(c1CC1CC1)-c1nc(N[C@H]2CC[C@H](N)CC2)ncc1Cl |
Relative Density. | 1.48 g/cm3 (Predicted) |
Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 80 mg/mL (221.68 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.